RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Protara Therapeutics Stock

Protara Therapeutics P/S 2024

Protara Therapeutics P/S

0

Ticker

TARA

ISIN

US74365U1079

WKN

A2P4JE

As of Nov 20, 2024, Protara Therapeutics's P/S ratio stood at 0, a 0% change from the 0 P/S ratio recorded in the previous year.

The Protara Therapeutics P/S history

Protara Therapeutics Aktienanalyse

What does Protara Therapeutics do?

Protara Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for rare and severe immune system disorders. It was founded in 2012 and is based in Tarrytown, New York. The company was formed through the merger of NeuroproteXeon, Inc. and Biokine Therapeutics Ltd, with the goal of developing a pipeline of novel therapeutics for rare immune system diseases. In 2018, the company was acquired by Protea Biosciences Group Inc. Protara's business model revolves around the discovery, development, and commercialization of innovative therapeutics for immune system disorders. The company utilizes various technologies and platforms, including its proprietary protein engine, to drive its innovation program. It currently has two main divisions: one focused on the development and commercialization of T-cell-engaging Bi-Specifics, a novel class of immunotherapeutics specialized in tumor antigen-specific T-cell activation, and another division offering innovative nanotechnology platforms for the development of drugs for the treatment of inflammatory and immune disorders. Protara's leading pipeline products include TULIP Bi-Specific (JNJ-63898081), a T-cell-engaging Bi-Specific against CD3 and BCMA in phase I/IIa clinical trials for patients with multiple myeloma, and RTX-240, a T-cell-engaging Bi-Specific against CD3 and PSMA in the development phase for patients with advanced solid tumors. The company also focuses on developing precursor molecules for T-cell-engaging Bi-Specifics and protein engineering and optimization technologies to enhance the effectiveness and half-life of immunotherapeutics. Additionally, Protara has proprietary nanoparticle platforms, known as NANOMAbs, with promising applications in the treatment of inflammatory and immune disorders such as COVID-19, lupus, dermal diseases, and others. In summary, Protara Therapeutics Inc is a leading biopharmaceutical company focused on innovative therapies for immune system disorders. Its pipeline includes T-cell-engaging Bi-Specifics and proprietary nanoparticle platforms with promising applications in the treatment of inflammatory and immune disorders. With its complex technology and protein development and optimization capabilities, Protara continues to create groundbreaking new treatment options for patients. Protara Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Protara Therapeutics's P/S Ratio

Protara Therapeutics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Protara Therapeutics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Protara Therapeutics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Protara Therapeutics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Protara Therapeutics stock

What is the price-to-earnings ratio of Protara Therapeutics?

The price-earnings ratio of Protara Therapeutics is currently 0.

How has the price-earnings ratio of Protara Therapeutics changed compared to last year?

The price-to-earnings ratio of Protara Therapeutics has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Protara Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Protara Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Protara Therapeutics affect the company?

An increase in the price-earnings ratio of Protara Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Protara Therapeutics affect the company?

A decrease in the price-earnings ratio of Protara Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Protara Therapeutics?

Some factors that influence the price-earnings ratio of Protara Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Protara Therapeutics pay?

Over the past 12 months, Protara Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Protara Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Protara Therapeutics?

The current dividend yield of Protara Therapeutics is .

When does Protara Therapeutics pay dividends?

Protara Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Protara Therapeutics?

Protara Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Protara Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Protara Therapeutics located?

Protara Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Protara Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Protara Therapeutics from 11/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/20/2024.

When did Protara Therapeutics pay the last dividend?

The last dividend was paid out on 11/20/2024.

What was the dividend of Protara Therapeutics in the year 2023?

In the year 2023, Protara Therapeutics distributed 0 USD as dividends.

In which currency does Protara Therapeutics pay out the dividend?

The dividends of Protara Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Protara Therapeutics

Our stock analysis for Protara Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Protara Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.